plp (139151)

PLP (139-151) is an amino acid fragment from positions 139 to 151 of myelin proteolipid protein (PLP), which is used to induce the relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) model.

Plp(139-151) trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64674.

[L144-PLP(139-151)], a peptide ligand of the T cell receptor (TCR), acts as a TCR antagonist specifically inhibiting the activation of encephalitogenic Th1 clones [1].

[Gln144]-PLP(139-151) is an experimental antigen employed to investigate the cross-reactivity of T cells to self and non-self antigens. It activates T cells by binding to the T-cell Receptor (TCR), initiating an immune response. It is useful in the study of autoimmune disease regulation.

[Leu144,Arg147]-PLP (139-151) is a modified peptide fragment derived from myelin proteolipid protein (PLP), where leucine and arginine have replaced tryptophan and histidine at positions 144 and 147, respectively. This mutant also functions as a T cell receptor (TCR) antagonist, inhibiting the activation of encephalitogenic Th1 clones in vitro. Additionally, [Leu144,Arg147]-PLP (139-151) can impede the progression of experimental autoimmune encephalomyelitis (EAE).

[SER140]-PLP(139-151) is a polypeptide fragment derived from the myelin-associated lipid protein.

[SER140]-PLP(139-151) acetate is a peptide fragment from myelin proteolipid protein (PLP).

[SER140]-PLP(139-151) (TFA) is a polypeptide fragment of the myelin lipid protein.